To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[18F\]F-PSMA-1007.
\[18F\]F-PSMA-N5 PET/CT was used for initial assessment of prostate cancer or detection of recurrence. The maximum standardized uptake value (SUVmax) was used to evaluate tumor uptake. The sensitivity, specificity, the number and accuracy of lesions identified and the distribution of lesions in each organ were calculated and compared with those of \[18F\]F-PSMA-1007 PET/CT.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Each subject receive a single intravenous injection of \[18F\]F-PSMA-1007, and undergo PET/CT imaging within the specificed time.
The First Affiliated Hospital of China University of Science and Technology(Anhui Provincial Hospital)
Hefei, Anhui, China
RECRUITINGStandard uptake value(SUV)
Standard uptake value(SUV) of \[18F\]F-PSMA-N5 and \[18F\]F-PSMA-1007 for each target lesion of subjects.
Time frame: 30 days
Diagnostic efficacy
The sensitivity, specificity and accuracy of \[18F\]F-PSMA-N5 and \[18F\]F-PSMA-1007 PET/CT were calculated.
Time frame: 30 days
Number of lesions
The number of lesions detected by \[18F\]F-PSMA-N5 and \[18F\]F-PSMA-1007 PET/CT.
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.